{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:51:01Z","timestamp":1781877061943,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04239-2","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:32:25Z","timestamp":1770136345000},"page":"2876-2882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Disproportionality analysis of hematologic adverse events associated with trastuzumab deruxtecan using the Japanese pharmacovigilance database"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0095-2293","authenticated-orcid":false,"given":"Yuko","family":"Kanbayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Morioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8882-8846","authenticated-orcid":false,"given":"Keiko","family":"Hosohata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"4239_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"LC Tsao","year":"2025","unstructured":"Tsao LC, Wang JS, Ma X, Sodhi S, Ragusa JV, Liu B, et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat Commun. 2025;16:3167. https:\/\/doi.org\/10.1038\/s41467-025-58266-8.","journal-title":"Nat Commun"},{"key":"4239_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03143-3","volume":"43","author":"J Lee","year":"2024","unstructured":"Lee J, Kida K, Koh J, Liu H, Manyam GC, Gi YJ, et al. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer. J Exp Clin Cancer Res. 2024;43:236. https:\/\/doi.org\/10.1186\/s13046-024-03143-3.","journal-title":"J Exp Clin Cancer Res"},{"key":"4239_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","volume":"80","author":"SJ Keam","year":"2020","unstructured":"Keam SJ. Trastuzumab deruxtecan: first approval. Drugs. 2020;80:501\u20138. https:\/\/doi.org\/10.1007\/s40265-020-01281-4.","journal-title":"Drugs"},{"key":"4239_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111682","volume":"183","author":"Z Xu","year":"2019","unstructured":"Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111682.","journal-title":"Eur J Med Chem"},{"key":"4239_CR5","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. N Engl J Med. 2024;391:2110\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407086.","journal-title":"N Engl J Med"},{"key":"4239_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","volume":"25","author":"K Raghav","year":"2024","unstructured":"Raghav K, Siena S, Takashima A, Kato T, den Van Eynde M, Pietrantonio F, et al. Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:1147\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(24)00380-2.","journal-title":"Lancet Oncol"},{"key":"4239_CR7","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1111\/cas.16234","volume":"115","author":"H Iwata","year":"2024","unstructured":"Iwata H, Xu B, Kim SB, Chung WP, Park YH, Kim MH, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer. Cancer Sci. 2024;115:3079\u201388. https:\/\/doi.org\/10.1111\/cas.16234.","journal-title":"Cancer Sci"},{"key":"4239_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102924","volume":"9","author":"SA Hurvitz","year":"2024","unstructured":"Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial. ESMO Open. 2024;9:102924. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102924.","journal-title":"ESMO Open"},{"key":"4239_CR9","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, et al. Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023;41:4852\u201363. https:\/\/doi.org\/10.1200\/JCO.23.01361.","journal-title":"J Clin Oncol"},{"key":"4239_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/oncolo\/oyae151","volume":"29","author":"GU Mehta","year":"2024","unstructured":"Mehta GU, Vellanki PJ, Ren Y, Amatya AK, Mishra-Kalyani PS, Pan L, et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. Oncologist. 2024;29:667\u201371. https:\/\/doi.org\/10.1093\/oncolo\/oyae151.","journal-title":"Oncologist"},{"key":"4239_CR11","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"},{"key":"4239_CR12","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"S Modi","year":"2020","unstructured":"Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1914510.","journal-title":"N Engl J Med"},{"issue":"847\u201355","key":"4239_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.09.005","volume":"23","author":"GP Dowling","year":"2023","unstructured":"Dowling GP, Daly GR, Keelan S, Boland F, Toomey S, Hill ADK, et al. Efficacy and safety of trastuzumab deruxtecan in breast cancer: a systematic review and meta-analysis. Clin Breast Cancer. 2023;23(847\u201355):e2. https:\/\/doi.org\/10.1016\/j.clbc.2023.09.005.","journal-title":"Clin Breast Cancer"},{"key":"4239_CR14","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/cncr.35349","volume":"130","author":"R Li","year":"2024","unstructured":"Li R, Hua M, Li J, Chen W, Xu L, Meng H, et al. The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and\/or pneumonitis: a systematic review and single-arm meta-analysis. Cancer. 2024;130:2968\u201377. https:\/\/doi.org\/10.1002\/cncr.35349.","journal-title":"Cancer"},{"key":"4239_CR15","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cortes","year":"2024","unstructured":"Cortes J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30:2208\u201315. https:\/\/doi.org\/10.1038\/s41591-024-03021-7.","journal-title":"Nat Med"},{"key":"4239_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01805-w","volume":"39","author":"Y Kanbayashi","year":"2022","unstructured":"Kanbayashi Y, Uchida M, Kashiwagi M, Akiba H, Shimizu T. Evaluation of lung adverse events with trastuzumab using the Japanese pharmacovigilance database. Med Oncol. 2022;39:219. https:\/\/doi.org\/10.1007\/s12032-022-01805-w.","journal-title":"Med Oncol"},{"key":"4239_CR17","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.2147\/TCRM.S168696","volume":"14","author":"S Oyama","year":"2018","unstructured":"Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, et al. Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Ther Clin Risk Manag. 2018;14:1599\u2013604. https:\/\/doi.org\/10.2147\/TCRM.S168696.","journal-title":"Ther Clin Risk Manag"},{"key":"4239_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/TCRM.S176620","volume":"15","author":"A Inada","year":"2019","unstructured":"Inada A, Hosohata K, Oyama S, Niinomi I, Mori Y, Yamaguchi Y, et al. Evaluation of medication-related osteonecrosis of the jaw using the Japanese Adverse Drug Event Report database. Ther Clin Risk Manag. 2019;15:59\u201364. https:\/\/doi.org\/10.2147\/TCRM.S176620.","journal-title":"Ther Clin Risk Manag"},{"key":"4239_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40261-019-00788-3","volume":"39","author":"K Hosohata","year":"2019","unstructured":"Hosohata K, Oyama S, Niinomi I, Wakabayashi T, Inada A, Iwanaga K. Comparison of safety profiles of new oral anticoagulants with warfarin using the Japanese spontaneous reporting database. Clin Drug Investig. 2019;39:665\u201370. https:\/\/doi.org\/10.1007\/s40261-019-00788-3.","journal-title":"Clin Drug Investig"},{"key":"4239_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1691\/ph.2020.0604","volume":"75","author":"H Kambara","year":"2020","unstructured":"Kambara H, Hosohata K, Nakatsuji T, Ueno S, Oyama S, Inada A, et al. Safety profile of vonoprazan compared with proton pump inhibitors: insight from a pharmacovigilance study. Pharmazie. 2020;75:527\u201330. https:\/\/doi.org\/10.1691\/ph.2020.0604.","journal-title":"Pharmazie"},{"key":"4239_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.5414\/CP203724","volume":"58","author":"I Niinomi","year":"2020","unstructured":"Niinomi I, Hosohata K, Oyama S, Inada A, Hirai T, Iwanaga K. Drug-induced thrombotic microangiopathy using the Japanese pharmacovigilance database. Int J Clin Pharmacol Ther. 2020;58:543\u20139. https:\/\/doi.org\/10.5414\/CP203724.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4239_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11:3\u201310. https:\/\/doi.org\/10.1002\/pds.668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"4239_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, Molokhia M, Cornelius VR. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36:995\u20131006. https:\/\/doi.org\/10.1007\/s40264-013-0061-7.","journal-title":"Drug Saf"},{"key":"4239_CR24","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.7150\/jca.86746","volume":"14","author":"F Liu","year":"2023","unstructured":"Liu F, Yin G, Xue S, Rehman FU, Liao D, Pan Y. Adverse event profile differences between trastuzumab emtansine and trastuzumab deruxtecan: a real-world, pharmacovigilance study. J Cancer. 2023;14:3275\u201384. https:\/\/doi.org\/10.7150\/jca.86746.","journal-title":"J Cancer"},{"key":"4239_CR25","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2115022.","journal-title":"N Engl J Med"},{"key":"4239_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"4239_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s12094-024-03383-x","volume":"26","author":"E Ciruelos","year":"2024","unstructured":"Ciruelos E, Garcia-Saenz JA, Gavila J, Martin M, Rodriguez CA, Rodriguez-Lescure A. Safety profile of trastuzumab deruxtecan in advanced breast cancer: expert opinion on adverse event management. Clin Transl Oncol. 2024;26:1539\u201348. https:\/\/doi.org\/10.1007\/s12094-024-03383-x.","journal-title":"Clin Transl Oncol"},{"key":"4239_CR28","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/jcpt.13777","volume":"47","author":"Z Guo","year":"2022","unstructured":"Guo Z, Ding Y, Wang M, Liu J, Zhai Q, Du Q. Safety of trastuzumab deruxtecan: a meta-analysis and pharmacovigilance study. J Clin Pharm Ther. 2022;47:1837\u201344. https:\/\/doi.org\/10.1111\/jcpt.13777.","journal-title":"J Clin Pharm Ther"},{"key":"4239_CR29","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s40264-023-01328-x","volume":"46","author":"JWY Chiu","year":"2023","unstructured":"Chiu JWY, Lee SC, Ho JC, Park YH, Chao TC, Kim SB, et al. Clinical guidance on the monitoring and management of trastuzumab deruxtecan (T-DXd)-related adverse events: insights from an Asia-Pacific multidisciplinary panel. Drug Saf. 2023;46:927\u201349. https:\/\/doi.org\/10.1007\/s40264-023-01328-x.","journal-title":"Drug Saf"},{"key":"4239_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/COC.0000000000001126","volume":"47","author":"Z Qureshi","year":"2024","unstructured":"Qureshi Z, Altaf F, Jamil A, Siddique R, Fatima E. Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+ and HER2-low breast cancer: an updated systematic review and meta-analysis of clinical trials. Am J Clin Oncol. 2024;47:535\u201341. https:\/\/doi.org\/10.1097\/COC.0000000000001126.","journal-title":"Am J Clin Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04239-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04239-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04239-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T12:57:41Z","timestamp":1781873861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04239-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["4239"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04239-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"24 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declared no potential competing Interests: with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval was not sought for this study, given the database-related, observational design without direct involvement of any research subjects. All results were obtained from data openly available online from the PMDA website (\n                      \n                      ,\n                      \n                      ). All data from the JADER were fully anonymized by the relevant regulatory authority before being accessed. All methods were therefore performed in accordance with the relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors give their consent for this manuscript to be published in\n                      Clinical and Translational Oncology\n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}